- Home
- ETY vs CLDX Comparison
ETY vs CLDX Comparison
Compare ETY & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ETY | CLDX |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | 2005 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ETY | CLDX |
|---|---|---|
| Price | $14.52 | $40.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $46.60 |
| AVG Volume (30 Days) | 246.6K | ★ 986.8K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,743,000.00 |
| Revenue This Year | N/A | $111.39 |
| Revenue Next Year | N/A | $235.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 87.78 |
| 52 Week Low | $13.12 | $19.72 |
| 52 Week High | $16.03 | $40.30 |
Technical Indicators
Market Signals| Indicator | ETY | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 55.19 | 67.38 |
| Support Level | $13.94 | $28.51 |
| Resistance Level | $14.75 | $40.30 |
| Average True Range (ATR) | 0.19 | 1.59 |
| MACD | 0.04 | 0.24 |
| Stochastic Oscillator | 68.76 | 97.50 |
Price Performance
Historical ComparisonAbout ETY Eaton Vance Tax-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Tax-mgd Dvsf Eq Inc Fd is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, and consumable fuels, and other sectors.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.